LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi announced today it has launched Gadoterate Meglumine Injection, USP, a bioequivalent and therapeutic equivalent substitute for the contrast agent ...
Approval marks a major milestone in reducing gadolinium exposure while maintaining diagnostic performance, aligning with clinical guidance to use the lowest effective dose MONTREAL, April 17, 2026 ...
Iopromide injection becomes the first FDA-approved contrast agent for visualizing known or suspected breast lesions in adult patients. The FDA has approved the iodine-based contrast agent iopromide ...
PRINCETON, N.J., Nov. 11, 2024 /PRNewswire/ -- Bracco Diagnostics Inc., the U.S. subsidiary of Bracco Imaging S.p.A., a leading global company in the diagnostic imaging business, is proud to announce ...
Designed for contrast media injections, the PowrSyringe is capable of an injection that is between 20 and 100% faster than a standard control syringe. Nothing beats the need for speed when it comes to ...
LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi announced today it will introduce a portfolio of generic contrast media agents in the United States, starting immediately with the launch of ...
Skoltech researchers and their colleagues have synthesized and tested protein-polymer microbubbles for use in medical ultrasound imaging of internal organs. Administered intravenously, the ...
Centargo compatible with Ultravist® (iopromide), Isovue® (iopamidol), Optiray® (ioversol), Omnipaque™ (iohexol) and now, Visipaque™ (iodixanol) Follows recent FDA clearance to expand the use of ...
Although contrast agents have an essential role in non-invasive imaging techniques, potential side effects limit their use. For example, both low- and iso-osmolar iodinated contrast media used in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results